中信國際電訊CPC榮獲三項業界大獎 內外展現網絡安全實力 ACN Newswire

中信國際電訊CPC榮獲三項業界大獎 內外展現網絡安全實力

香港, 2024年12月4日 - (亞太商訊 via SeaPRwire.com) - 中信國際電訊集團有限公司(「中信國際電訊」,香港交易所股份代號:1883)全資擁有的中信國際電訊(信息技術) 有限公司(「中信國際電訊CPC」) 宣布勇奪三項業界大獎 ,肯定中信國際電訊CPC深耕網絡安全的卓越表現,表揚專業團隊深厚的行業知識與技術、員工高度的網絡安全意識及尖端的創新解決方案,以滿足市場對不斷增長的網絡安全需求 ,應對日益猖獗的網絡威脅和挑戰。 三項業界大獎包括:- 香港互聯網註冊管理有限公司(HKIRC)「共建員工防火牆」嘉許計劃2024 白金級獎 ;- Fortinet「2024年度最佳託管安全服務供應商」獎項 (Top MSSP of the Year 2024);- Green Radar「2024 年度最佳企業業務合作夥伴」獎項 (Top Partner Enterprise Business FY24 )中信國際電訊 CPC 行政總裁黃政華先生表示:「該三項業界大獎展示我們對推動內部“員工防火牆”文化的承諾,同時透過我們的網絡安全專家團隊向企業客戶提供全面的解決方案,彰顯了我們內外實力的堅實基礎。業界對我們的肯定將激勵我們持續提升網絡安全創新方案,期望帶來更多的市場機遇,共同推動行業高質量發展。我們有信心,旗艦信息安全解決方案“TrustCSI™ 3.0雲網神盾” 在網絡安全市場保持領先優勢,鞏固我們作為前沿網絡安全領導者地位。」 HKIRC「共建員工防火牆」嘉許計劃香港互聯網註冊管理有限公司 (HKIRC) 與國際信息系統審計協會中國香港分會 (ISACA) 聯合舉辦的「共建員工防火牆」嘉許計劃圓滿舉行 ,參加機構涵蓋了銀行、物業管理、零售等行業的中小企及大型企業。該計劃旨在表彰得獎企業在過去一年內意識到網絡安全重要性並積極提升員工網絡安全意識的努力。「共建員工防火牆」嘉許計劃鼓勵更多機構採取積極的措施推廣「員工防火牆(Human Firewall)」理念 ,透過多種渠道如培訓、政策、溝通、演習等提高員工防護意識。最高級別白金級獎需要符合所有5項評審標準,包括網絡安全培訓 、網絡釣魚演習 、網絡安全政策 、通報渠道及網絡安全資訊傳遞 。中信國際電訊CPC 榮獲最高級別之白金級認證,表揚其過去不但致力在網絡安全技術上不斷提升、在系統和政策方面全面優化,並推出“TrustCSI™ 3.0 雲網神盾”資安服務,創新的服務框架,配備主動防禦技術以應對快速迭代的網絡威脅。 同時培養員工對網絡安全意識文化的決心,透過全球員工強度訓練及網絡安全演練,構建為公司的第二道防線,防範並能有效應對不斷變化的網絡威脅。 共創共贏,構建更堅固的防禦生態圈此外,中信國際電訊CPC 再次榮獲兩家網絡安全服務生態圈夥伴Fortinet及Green Radar頒發多個卓越獎項,彰顯其在全球性合作策略和網絡安全領域高質量的協同效益與服務能力,透過持續的技術創新和與生態圈夥伴的緊密合作,中信國際電訊CPC得以不斷提升産品和服務質量,以滿足市場對網絡安全方案的需求,並超越競爭對手。其中包括在 2023 年推出的 TrustCSI™ 3.0 雲網神盾,通過智能技術重塑安全運營中心(SOC)的核心服務能力,為企業提供主動式防禦,將AI 應用融入其業務中,優化智能營運。首先, Fortinet頒發的「2024 年度最佳託管安全服務供應商」獎項肯定了中信國際電訊CPC 前沿的託管安全服務,超越業界標準。另外,Green Radar「2024 年度最佳企業業務合作夥伴」獎項表揚中信國際電訊CPC與合作夥伴携手推動創新解决方案,以滿足企業客戶獨特的網絡安全需求。積極提升內外網絡安全及創新技術中信國際電訊CPC無論對內或對外,一直積極展現卓越的網絡安全能力。在對內方面,中信國際電訊CPC致力培育員工網絡安全意識,而員工在工作上時刻保持警惕和採用主動的防禦措施,體現了對網絡安全的最佳實踐,保護公司的數碼資產。在對外方面,中信國際電訊CPC致力成為企業可信賴的TechOps 信息安全賦能者,旗下的網絡安全專家團隊具備前瞻思維和追求卓越成就的精神,透過專業服務和創新定製的解決方案,助力客戶輕鬆及靈活地應對瞬息萬變的數碼環境。秉持“創新不斷”服務理念,中信國際電訊CPC持續將人工智能技術整合到信息安全產品組合中,提供先進網絡安全解決方案以應對越發猖獗的網絡威脅。中信國際電訊CPC最新的TrustCSI™ AI滲透測試(AI Pentest)服務如同網絡AI掃地機器人,24x7全自動化工作,協助企業找出網絡中的致命漏洞,建立強大的防禦機制 。為了強化企業客戶內外部的漏洞保護,中信國際電訊CPC特別提供了一個最新內外評估組合方案,協助客戶通過對內的AI滲透測試服務,同時,進行攻擊面管理 (Attack Surface Management),增強公司對外部漏洞的抵禦能力,並有系統地優化漏洞識別、排列漏洞優次、補救和持續監控等攻擊,透過多管齊下的防護措施降低潛在的網絡攻擊風險,提升企業安全管理策略。詳情可瀏覽 https://www1.citictel-cpc.com/promotion/2411XmasOffer/index-TC.html中信國際電訊CPC簡介中信國際電訊(信息技術)有限公司(「中信國際電訊CPC」)是中信國際電訊集團有限公司(香港交易所股份代號:1883)的全資附屬公司,一直矢志透過先進技術及旗艦解決方案,包括TrueCONNECT™專用網絡服務、TrustCSI™信息安全解決方案、DataHOUSE™全球統一雲數據中心解決方案及SmartCLOUD™雲端運算解決方案,為全球跨國企業提供綜合數碼解決方案, 滿足不同行業的ICT服務需求。憑借「創新‧不斷」的服務理念,中信國際電訊CPC積極利用創新技術,提煉“技術賦能”,將人工智能、擴增實境、大數據、物聯網和其他尖端新興技術,融合深度學習及智能數據分析技術,轉化為“數據賦能”生成式AI+應用,重塑企業智能營運之旅。中信國際電訊CPC以「服務在地,連接全球」的優勢,承諾為客戶提供最優質的一站式ICT服務。全球化網絡資源連接近170個服務據點、60多個SDWAN 網關;21個雲服務中心、30多個數據中心及3個全天候運作的安全運作中心,服務遍布约160個國家和地區,無縫連接亞洲、歐美、非洲、中東以及中亞等地區 。透過全球化服務佈局,多年不斷深耕各個行業與領域經驗,一系列國際認證(SD-WAN Ready, ISO 9001、14001、20000、27001 及27017),確保為企業提供國際化標準及專業在地服務能力,成為客戶信賴的信息智能化服務供應商。請瀏覽 www.citictel-cpc.com 獲取更多資訊。傳媒查詢:Catherine Yuen中信國際電訊CPC(852) 2170 7536電郵:catherine.yuen@citictel-cpc.com Copyright 2024 亞太商訊 via SeaPRwire.com.
More
Sweetness Affecting Both the Young and Old: Prevent Diabetes with LAC This World Diabetes Day ACN Newswire

Sweetness Affecting Both the Young and Old: Prevent Diabetes with LAC This World Diabetes Day

SINGAPORE, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) - How much sugar does a Singaporean typically take in a day? In a recent speech by Health Minister Mr. Ong Ye Kung, Singapore is too sweet. While the average daily sugar intake of Singaporeans has fallen from 60g in 2018 to 56g in 2022, this number still works out to about 11 teaspoons of daily sugar consumption, about 10% higher than the ideal intake of less than 50g.Amid an ageing population, the younger generation in Singapore is also increasingly affected by this chronic condition, highlighting a growing national health concern related to sugar consumption.Sugar, a common mis-solution to anxiety, often provides a sense of fleeting comfort. The instant boost in dopamine from sugar can create a cycle of dependency, giving temporary relief from stress or anxiety but contributing to harmful physical effects, such as inflammation, weight gain, and insulin resistance.The overconsumption of sugar, combined with sedentary lifestyles and other unhealthy dietary habits have contributed to diabetes becoming a major global health crisis today – Alarmingly, diabetes rates are rising among the younger generation, including both teenagers and young adults, contributing to nearly half a million cases in Singapore. Astonishingly, 40% of Singaporeans remain unaware of their pre-diabetic status, an often silent condition that could lead to type 2 diabetes.Diabetes is a chronic condition that if left unmanaged, can lead to serious health complications, including an increased risk of cardiovascular disease, kidney failure, nerve damage or even vision loss. However, type 2 diabetes can be prevented through proactive lifestyle changes, including healthy eating, regular physical activity, so as to maintain optimal blood sugar levels.In line with World Diabetes Day on 14 November, LAC (pronounced as L-A-C) is dedicated to highlight the importance of taking preventative measures against diabetes. By incorporating supplements that support blood sugar regulation and reduce carbohydrate absorption, along with a healthy diet and increased physical activity, individuals can maintain their glucose levels and maintain their metabolic health.LAC GlucoX is designed to support healthy glucose levels. Formulated with bitter melon and Fibersol-2, Banaba leaf, Gymnema, Chromium and Brown Seaweed, GlucoX helps slow down carbohydrate absorption and optimises glucose utilisation, supporting individuals in managing their blood sugar levels effectively.LAC Bitter Melon Formula, is formulated with Momordica Charantia Polysaccharide (MCP), a key compound from bitter melon known for its ability to support healthy blood glucose levels. It enhances the body’s ability to regulate insulin production and supports the overall metabolic health of individuals. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
CleverTap Report: 46% of Product Managers Cite Resource Limitations as Top Barrier to App and Web Experimentation ACN Newswire

CleverTap Report: 46% of Product Managers Cite Resource Limitations as Top Barrier to App and Web Experimentation

SAN FRANCISCO, CA & MUMBAI, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - CleverTap, the all-in-one engagement platform, has released its market research report on “The State of App and Web User Experience Optimization”. The report sheds light on how digital-first brands are leveraging experimentation and personalization on their apps and websites to drive customer engagement and business growth. It also highlights roadblocks faced by marketers and product managers while experimenting with the UI, workflows, and functionality across apps and websites.For a thorough understanding of the current landscape, this report draws insights from a diverse group of respondents – with data gathered through structured surveys and in-depth interviews – representing organizations with over two million customers across 50+ countries. This includes VPs, CMOs, and product managers ranging from startups to large enterprises across various industries. – Together, they offer valuable insights into how businesses optimize app and web experiences to drive customer engagement and business growth.While 95% of surveyed product managers and 88% of marketers believe that the right user experience is essential for driving customer engagement and retention — many report significant challenges to effectively experimenting with app and web user experiences. Despite recognizing its importance, they reported difficulties such as limited resources, data gaps, and technical constraints that hinder their ability to innovate and deliver impactful user experiences. Other notable findings from the report include -81.9% of product managers rarely experiment with their app and web experiences before making changes to them. The top challenges quoted include lack of resources (46%), inadequate data and analytics (31%), and technical issues (19%)54% of product managers are unable to support marketers in experimenting with onboarding flows, banner placement, homepage content and other similar app and web experiences.81% of marketers believe it would make a significant impact if they could independently experiment with multiple variations of web and app experiences within a no-code framework provided by their product management function.Commenting on the report, Jacob Joseph, Vice President - Data Science, CleverTap said, “With consumer expectations constantly rising, brands need to go beyond perfecting their channel strategies and also focus on enhancing the in-app and web experiences to drive results from their marketing efforts. Since all channels ultimately lead users to the app or website, an unsatisfactory experience there can render all your efforts ineffective and become a missed opportunity. Personalization and experimentation on apps and websites are critical to reducing churn and driving growth, yet resource constraints and data gaps hinder marketers and product managers. We are committed to helping businesses navigate these challenges with CleverTap’s Product Experiences, which offers effortless ways to personalize and experiment with app and web experiences driving stronger engagement and lasting brand loyalty."For more information and insights download the report here. About CleverTapCleverTap is the leading all-in-one customer engagement platform that helps brands unlock limitless customer lifetime value. CleverTap is trusted by over 2000 brands like Decathlon, Domino’s, Levis, Jio, Emirates NBD, Puma, Croma (A Tata Enterprise), Swiggy, SonyLIV, Axis Bank, AirAsia, TD Bank, Ooredoo, and Tesco to help build personalized experiences for all their customers. The platform is powered by TesseractDB™ – the world’s first purpose-built database for customer engagement, offering speed and cost efficiency at scale.Backed by top-tier investors such as Accel, Peak XV Partners, Tiger Global, CDPQ and 360 One, the company is headquartered in San Francisco, with presence across Seattle, London, São Paulo, Bogota, Mexico, Amsterdam, Sofia, Dubai, Mumbai, Bangalore, Singapore, Vietnam, and Jakarta.For more information, visit clevertap.com or follow us on:LinkedIn: https://www.linkedin.com/company/clevertap/ X: https://twitter.com/CleverTap Forward-Looking StatementsSome of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release.Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness, or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction.For more information:SONY SHETTYDirector, Communications, CleverTap+91 9820900036sony@clevertap.comASHMIT CHAUDHARYAssociate Consultant, Archetype+91 8850752121ashmit.chaudhary@archetype.co Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy ACN Newswire

Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy

- Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission and 10 out of 11 (91%) achieved immunological complete remission.- In the high dose cohort, 6 out of 7 (85.7%) patients achieved overall clinical remission and all patients achieved immunological complete remission by week 24.- EVER001 was generally safe and well tolerated. No clinically significant adverse events typically associated with earlier-generation BTK inhibitors, such as bleeding, arrhythmia, severe infection, leukopenia, thrombocytopenia, or severe liver function impairment, were reported.SHANGHAI, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK,“Everest”, or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced positive results in the ongoing Phase 1b/2a clinical trial for the treatment of primary membranous nephropathy (pMN) with EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor. In an analysis of the data available as of September 13th, 2024, results from the Phase 1b/2a clinical trial showed that for patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission1 and 10 out of 11 (91%) achieved immunological complete remission (ICR)2. In the high dose cohort, 6 out of 7 (85.7%) patients achieved overall clinical remission and all patients achieved ICR by week 24.EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of autoimmune renal diseases. Compared to covalent irreversible BTK inhibitors, EVER001 offers improved selectivity while maintaining high potency, thereby potentially avoiding many of the side effects associated with earlier-generation BTK inhibitors. Everest Medicines holds global rights to EVER001 for the treatment of renal diseases.The Phase 1b/2a clinical trial of EVER001 for the treatment of pMN is an ongoing trial conducted in China. A total of 31 patients with biopsy-proven pMN who tested positive for anti-PLA2R autoantibodies were enrolled into two cohorts. The total treatment duration was 36 weeks. Based on the patient data collected by September 13th, 2024, in the low-dose cohort, the geometric least squares mean 24-hour proteinuria decreased by 78.3% at week 36 compared to baseline, while the high-dose cohort achieved a 73.8% reduction by week 24. EVER001 treatment induced greater than 90% reductions in anti-PLA2R antibody as early as week 24 in the low-dose cohort and week 12 in the high-dose cohort. EVER001 was generally safe and well tolerated. No clinically significant adverse events typically associated with earlier-generation BTK inhibitors, such as bleeding, arrhythmia, severe infection, leukopenia, thrombocytopenia, or severe liver function impairment, were reported."We are excited to see the encouraging results in this preliminary analysis of our Phase 1b/2a clinical proof-of-concept trial of EVER001. This demonstrates the potential of EVER001 as a next-generation BTK inhibitor for the treatment of various autoimmune renal diseases, including pMN. "Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, said:"This data release marks the first time Everest Medicines has disclosed results from its global pipeline. We look forward to completing this trial and sharing detailed data in future conferences and publications. Moving forward, we will continue to drive the global clinical development of EVER001, to meet patients' urgent clinical needs.”Membranous nephropathy is a common pathological type of nephrotic syndrome in adults, and its prevalence in China has been increasing, ranking second only to IgA nephropathy3. There are about 2 million patients with pMN in China, with an estimated 80,000 to 100,000 patients in the United States, 80,000 in Europe, and 40,000 in Japan. There are no approved drugs for this indication worldwide. The current treatment goal is to improve remission rates, reduce high relapse rates, and minimize the risk of chronic toxicity caused by currently available treatments. More than one-third of pMN patients still progress to end-stage renal disease under current standards of care.This Phase 1b/2a clinical trial was approved by the Center for Drug Evaluation of the National Medical Products Administration in September 2022 to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of EVER001 in Chinese patients with glomerular diseases characterized by proteinuria. The previously published results of a Phase 1 study conducted in healthy Chinese and Australian subjects conducted by SinoMab BioScience indicate that EVER001 has high selectivity, excellent pharmacokinetic properties, a good safety profile, and strong target binding.About EVER001EVER001 (previously known as XNW1011) is a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in development globally for the treatment of renal diseases. BTK is an essential component of the B-cell receptor signaling pathways that regulate the survival, activation, proliferation, and differentiation of B lymphocytes. Targeting BTK with small molecule inhibitors has been demonstrated to be an effective treatment option for B-cell lymphomas and autoimmune diseases. Based in part on results from a completed phase 1 trial with healthy subjects conducted by SinoMab in China, EVER001 exhibited high selectivity, excellent pharmacokinetics properties, strong target binding and a safety profile that supports continued clinical development.Under an exclusive licensing agreement with Sinovent Pharmaceuticals and SinoMab BioScience, Everest owns global rights to develop, produce and commercialize EVER001 for the treatment of renal diseases.Investor Calls InformationEverest Medicines will hold investor calls on the data results from EVER001 Phase 1b/2a clinical study in primary membranous nephropathy. EVER001 is a next-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor, and Everest owns the global rights to develop EVER001 for the treatment of renal diseases.The English session of the conference call will be held at 9:00 AM on Dec. 4, 2024, Beijing Time (8:00 PM U.S. Eastern Time on Dec. 3, 2024) and the Mandarin session of the conference call will be held at 10:30 AM Beijing Time on the same day (9:30 PM U.S. Eastern Time on Dec. 3, 2024).The conference calls can be accessed by the following links:For English Session:Time: 9:00 AM Beijing Time, Wednesday, Dec. 4, 2024 (8:00 PM U.S. Eastern Time on Dec. 3, 2024)Pre-Registration Link: https://www.acecamptech.com/eventDetail/60510700Webcast Link:https://www.acecamptech.com/meeting_live/70512679/774680?event_id=60510700Alternatively, participants may dial in to the conference call using below dial-in information:United States: +1-646-2543594 (EN)Chinese Mainland: +86-10-58084166 (EN), +86-10-58084199 (CN)Hong Kong, China: +852-30051313 (EN), +852-30051355 (CN)United Kingdom: +44-12-1368-0466 (EN)International: +1-866-6363243 (EN)Password: 842080For Mandarin Session:Time: 10:30 AM Beijing Time, Wednesday, Dec. 4, 2024 (9:30 PM U.S. Eastern Time on Dec. 3, 2024)Webcast Link: https://s.comein.cn/n3arj55sAlternatively, participants may dial into the conference call using below dial-in information:United States: +1-646-3578788, +1-408-7093255Chinese Mainland: 400-969-8928, 400-806-3263Hong Kong, China: +852-301-83602Taiwan, China: +886-226563394, +886-277417882Singapore: +65-64075649, +65-66220840United Kingdom: +44-2070970018 International: +86-2362737123Password: 377570The replay of English session will be available shortly after the call and can be accessed by visiting the Company’s website at http://www.everestmedicines.com.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.Forward-Looking Statements:This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.References:1.Overall clinical remission (complete remission or partial remission): 24h proteinuria complete remission (CR): 24h proteinuria < 0.3g/24 h; 24h proteinuria partial remission (PR): 24h proteinuria < 3.5g/24h, but ≥0.3g/24 h, and reduction > 50%, regardless of eGFR or the serum albumin level from baseline.2. Immunological complete remission (ICR): anti-PLA2R titer < 20RU/ml (negative).3. Expert consensus on the application of rituximab in the treatment of membranous nephropathy, Chin J Intern Med, March 2022, Vol. 61, No. 3. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
雲頂新耀宣佈治療原發性膜性腎病的新型BTK抑制劑EVER001在1b/2a期臨床試驗階段性數據中取得積極結果 ACN Newswire

雲頂新耀宣佈治療原發性膜性腎病的新型BTK抑制劑EVER001在1b/2a期臨床試驗階段性數據中取得積極結果

- 在已完成36周治療的低劑量組患者中,81.8%(9/11)的患者實現臨床緩解,高劑量組中已完成24周治療的患者已有85.7%(6/7)實現臨床緩解。- 除低劑量組的1例患者外,其他所有完成36周治療的低劑量組患者,以及所有經24周治療的高劑量組患者分別在36周和24周都實現了免疫學完全緩解。- EVER001總體安全性和耐受性良好。未見在其他共價非可逆BTK抑制劑上觀察到的有臨床意義的不良事件,如出血、心律失常、嚴重感染、白細胞減少、血小板減少、嚴重肝功能損傷等。上海, 2024年12月4日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀(HKEX 1952.HK)是一家專注于創新藥研發、臨床開發、製造和商業化的生物製藥公司,今日宣佈新一代共價可逆布魯頓酪氨酸激酶(BTK)抑制劑EVER001膠囊(又名:XNW1011)在治療原發性膜性腎病(primary membranous nephropathy,pMN)的1b/2a期臨床試驗階段性資料取得積極結果。直至9月13日的資料截止日期,結果顯示,在已完成36周治療的低劑量組患者中,81.8%(9/11)的患者實現臨床緩解,高劑量組中已完成24周治療的患者已有85.7%(6/7)實現臨床緩解。除低劑量組的1例患者外,其他所有完成36周治療的低劑量組患者,以及所有經24周治療的高劑量組患者分別在36周和24周都實現了免疫學完全緩解。EVER001是一款適用於自身免疫性腎臟疾病的共價可逆BTK抑制劑。與共價不可逆BTK抑制劑相比,EVER001作為一款潛在的同類最佳產品,在保持高活性的同時具有高選擇性,避免持續抑制帶來的毒副作用。雲頂新耀擁有這款產品用於腎病治療的全球權益。EVER001治療原發性膜性腎病的1b/2a期臨床試驗為一項正在進行中的中國研究。共有31名經腎臟活檢證實的抗-PLA2R自身抗體陽性的原發性膜性腎病患者分別入組低劑量組和高劑量組,接受EVER001共36周的治療。截至2024年9月13日的資料分析,低劑量組的24小時蛋白尿幾何平均值(最小二乘法)在36周相較於基線下降78.3%,而高劑量組在24周即出現73.8%的下降。抗-PLA2R自身抗體水準在資料截止日期時已達到接近100%的下降,而早在低劑量組的24周和高劑量組的12周,抗-PLA2R自身抗體下降已超過90%。EVER001總體安全性和耐受性良好。未見在其他共價非可逆BTK抑制劑上觀察到的有臨床意義的不良事件,如出血、心律失常、嚴重感染、白細胞減少、血小板減少、嚴重肝功能損傷等。雲頂新耀首席執行官羅永慶表示:「非常高興看到EVER001在此次公佈的階段性資料中取得了積極的結果。這顯示了EVER001作為新一代BTK抑制劑,對包括原發性膜性腎病在內的多種自身免疫性腎病治療的巨大潛力。迄今為止,全球沒有獲批原發性膜性腎病適應症的藥物。作為首個公佈的具有全球權益的管線產品資料,EVER001在原發性膜性腎病患者中取得的階段性結果令人鼓舞。我們也期待該1b/2a期臨床試驗的完成及更多相關資料的發表。我們將繼續推進EVER001的全球臨床開發,以最快速度滿足患者的臨床需求。」膜性腎病為成人腎病綜合征常見的病理類型,在我國的患病率呈逐年升高的趨勢,是發病率僅次於IgA腎病的原發性腎小球腎炎1。我國目前有約200萬原發性膜性腎病患者,而在美國約有8萬-10萬患者,歐洲約8萬患者,日本約4萬患者。目前全球沒有獲批此適應症的藥物。超過1/3的原發性膜性腎病患者最終將進展為終末期腎病,全球亟需研發能提高治療緩解率、降低高復發率、減少慢性腎毒性風險的治療藥物。此項1b/2a期臨床試驗於2022年9月獲得中國國家藥品監督管理局藥品審評中心批准,用於評價EVER001在蛋白尿為特徵的腎小球疾病的中國患者中的安全性、療效、藥代動力學和藥效學。此前公佈的中國抗體製藥在中國健康受試者中進行的1期研究結果表明,EVER001具有高選擇性、優異的藥代動力學特徵、良好的安全性特徵以及強大的靶點結合力。關於EVER001EVER001膠囊(又名:XNW1011)是新一代共價可逆的布魯頓酪氨酸激酶(BTK)抑制劑,正在全球範圍內開發用於治療腎病。BTK是B細胞受體信號通路的重要組成部分,可調節B淋巴細胞的存活、啟動、增殖和分化。應用小分子抑制劑靶向BTK是治療B細胞淋巴瘤和自身免疫性疾病的有效選擇。中國抗體製藥在國內完成的健康受試者I期研究結果表明,EVER001具有高選擇性、優異的藥代動力學特徵、強大靶點結合力和良好的安全性特徵,研究結果支援其進一步臨床開發。根據與信諾維醫藥和中國抗體製藥的獨家授權合約,雲頂新耀擁有在全球開發、生產和商業化EVER001用於治療腎病的權利。投資人會議公司將舉行中英文投資人線上會議,公佈新一代共價可逆布魯頓酪氨酸激酶(BTK)抑制劑 EVER001膠囊治療原發性膜性腎病的1b/2a期臨床試驗資料。雲頂新耀擁有EVER001在全球範圍內開發用於治療腎病領域的權益。英文場次將於北京時間2024年12月4日上午9時(美國東部時間12月3日晚上8時)舉行;中文場次將於北京時間同日上午10:30時(美國東部時間12月3日晚上9:30時)舉行。英文會議:會議時間:北京時間2024年12月4日,星期三,上午9時(美國東部時間12月3日晚上8時)提前註冊連結:https://www.acecamptech.com/eventDetail/60510700會議直播連結:https://www.acecamptech.com/meeting_live/70512679/774680?event_id=60510700同時,參會者也可以使用以下撥入資訊撥入電話會議:美國:+1-646-2543594 (EN)中國大陸:+86-10-58084166 (EN),+86-10-58084199 (CN)中國香港:+852-30051313 (EN),+852-30051355 (CN)英國:+44-12-1368-0466 (EN)國際:+1-866-6363243 (EN)會議代碼:842080中文會議:會議時間:北京時間2024年12月4日,星期三,上午10:30時(美國東部時間12月3日晚上9:30時)會議直播連結:https://s.comein.cn/n3arj55s同時,參會者也可以使用以下撥入資訊撥入電話會議:美國:+1-646-3578788,+1-408-7093255中國大陸:400-969-8928,400-806-3263中國香港:+852-301-83602中國台灣:+886-226563394,+886-277417882新加坡:+65-64075649,+65-66220840英國:+44-2070970018海外:+86-2362737123會議密碼:377570英文會議結束後,您可以通過訪問雲頂新耀官網(http://www.everestmedicines.com)收聽英文會議重播。關於雲頂新耀雲頂新耀是一家專注于創新藥和疫苗研發、臨床開發、製造和商業化的生物製藥公司,致力於滿足亞洲市場尚未滿足的醫療需求。雲頂新耀的管理團隊在中國及全球領先製藥企業從事過高品質研發、臨床開發、藥政事務、化學製造與控制(CMC)、業務發展和商業化運營,擁有深厚的專長和豐富的經驗。雲頂新耀已打造多款疾病首創或者同類最佳的藥物組合,公司的治療領域包括腎科疾病、感染性和傳染性疾病、自身免疫性疾病。有關更多資訊,請訪問公司網站:www.everestmedicines.com。前瞻性聲明本新聞稿所發佈的信息中可能會包含某些前瞻性表述,乃基於本公司或管理層在做出表述時對公司業務運營情況及財務狀況的現有看法、相信、和現有預期,可能會使用「將」、「預期」、「預測」、「期望」、「打算」、「計畫」、「相信」、「預估」、「確信」及其他類似詞語進行表述。這些前瞻性表述並非對未來業績的保證,會受到風險、不確定性及其他因素的影響,有些乃超出本公司的控制範圍,難以預計。因此,受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展等各種因素及假設的影響,實際結果可能會與前瞻性表述所含資料有較大差別。本公司及各附屬公司、各位董事、管理人員、顧問及代理未曾且概不承擔更新該稿件所載前瞻性表述以反映在本新聞稿發布日後最新信息、未來項目或情形的任何義務,除非法律要求。參考文獻:1.利妥昔單抗在膜性腎病中應用的專家共識,中華內科雜誌2022年3月第61卷第3期 Copyright 2024 亞太商訊 via SeaPRwire.com.
More
Machine learning used to optimise polymer production ACN Newswire

Machine learning used to optimise polymer production

TSUKUBA, Japan, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - Polymers, such as plastics, are essential in many aspects of life and industry, from packaging and cars to medical devices and optic fibres. Their value comes from diverse properties that are largely determined by their monomers – the single chemical units – that make up a polymer. Unfortunately, it can be challenging to control the chemical behaviour of monomers during manufacture to achieve a desired outcome.The flow synthesis reactor with two bottles containing a monomer, initiator and solvent mixed using a micromixer. The synthesis is controlled with AI-based design of experimental conditions such as the temperature and a flow rate. Now, a team of researchers led by Professor Mikiya Fujii of the Nara Institute of Science and Technology in Japan have used machine learning to mathematically model the polymerization process and reduce the need for time-consuming and expensive experimentation. Their results have been published in the journal Science and Technology of Advanced Materials: Methods.Machine learning algorithms need data, so the researchers designed a polymerization process that would quickly and efficiently generate experimental data to feed into the mathematical model. The target molecule was a styrene-methyl methacrylate co-polymer, which was made by mixing styrene and methyl methacrylate monomers, both already dissolved in a solvent with an added initiator substance, then heating them in a water bath.The team also used a method called flow synthesis, in which the two monomer solutions are mixed and heated in a constant flow. This allows for better mixing, more efficient heating, and more precise control of heating time and flow rate, which makes it ideal for use with machine learning.The modelling evaluated the effect of five key variables in the polymerization process: the concentration of the initiator, the ratio of solvent to monomer, the proportion of styrene, the temperature of the reaction, and the time spent in the water bath. The goal was to have an end product with as close to 50% styrene as possible.Once enough experimental data was available, the machine learning process took only five cycles of calculation to achieve the ideal proportion of styrene to methyl methacrylate. The results showed that the key was a lower temperature and longer time in the water bath, as well as lowering the relative concentration of the monomer in the solvent. The researchers were surprised to discover that the solvent concentration was just as important as the proportion of monomers going into the mix.“Our results demonstrate that machine learning not only can explicitly reveal what humans may have implicitly taken for granted but can also provide new insights that weren’t recognized before,” Professor Mikiya Fujii says. “The use of machine learning in chemistry could open the door for smarter, greener manufacturing processes with reduced waste and energy consumption.”Further informationMikiya FujiiNara Institute of Science and TechnologyEmail: fujii.mikiya@ms.naist.jp Paper: https://doi.org/10.1080/27660400.2024.2425178About Science and Technology of Advanced Materials: Methods (STAM-M)STAM Methods is an open access sister journal of Science and Technology of Advanced Materials (STAM), and focuses on emergent methods and tools for improving and/or accelerating materials developments, such as methodology, apparatus, instrumentation, modeling, high-through put data collection, materials/process informatics, databases, and programming. https://www.tandfonline.com/STAM-M Dr Yasufumi NakamichiSTAM Publishing DirectorEmail: NAKAMICHI.Yasufumi@nims.go.jp Press release distributed by Asia Research News for Science and Technology of Advanced Materials. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
DeAgentAI and OKX Wallet Join Forces: $50K DA Token Airdrop for Web3 Enthusiasts ACN Newswire

DeAgentAI and OKX Wallet Join Forces: $50K DA Token Airdrop for Web3 Enthusiasts

SINGAPORE, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) - OKX, the leading cryptocurrency exchange, has partnered with DeAgentAI, the first AI-driven feedback incentive protocol in Web3, to launch an exclusive airdrop campaign. Starting December 3rd, users can complete simple tasks on OKX Wallet to win a share of $50,000 worth of DA tokens.Click here to join the campaign: https://www.okx.com/web3/giveawayParticipating in the DeAgentAI and OKX Wallet airdrop is easy. Download the OKX Wallet, follow DeAgentAI social media networks, and complete a few simple tasks such as sharing campaign posts, and you can claim your rewards. The campaign runs from December 3rd for two weeks-don't miss out!This collaboration brings users unparalleled opportunities to explore advanced AI technology while enjoying the benefits of a secure and user-friendly wallet. With rewards of $50,000 worth of DA tokens, the initiative encourages users to explore Web3 in an innovative and incentivized environment. DeAgentAI and OKX Wallet aim to foster adoption and empower users in the rapidly evolving crypto space.About DeAgentAIDeAgentAI is a trailblazer in Web3 technology, introducing the first AI feedback mechanism incentive protocol that achieves "proof of insight" by integrating user feedback into the model training process. Its flagship product, AlphaX, combines advanced MOE and Transformer architectures to predict BTC and ETH price trends with over 80% accuracy.What is OKX's Web3 Wallet?OKX Wallet complements this innovation with its secure and user-friendly interface tailored for decentralized finance (DeFi) and Web3 applications. As a leading wallet in the crypto space, OKX Wallet enables seamless integration with platforms like DeAgentAI, empowering users to engage in token giveaways, explore cutting-edge AI tools, and participate in the rapidly growing Web3 ecosystem.Contact InformationYves-Alexandre d'OuradouFounderdeagent.ai@gmail.com(001) 2024989991Source: DeAgentAI Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Japan Maritime Defense Force Selects SeaGuardians From GA-ASI ACN Newswire

Japan Maritime Defense Force Selects SeaGuardians From GA-ASI

SAN DIEGO, CA, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) - The Japan Maritime Self-Defense Force (JMSDF) has selected the General Atomics Aeronautical Systems, Inc. (GA-ASI) SeaGuardian® Remotely Piloted Aircraft (RPA) systems for its Long Endurance Unmanned Aerial Vehicle program. This follows JMSDF use of SeaGuardian since May 2023 as part of its Medium-Altitude, Long Endurance (MALE) RPA System Trial Operations Project.SeaGuardian has been used by JMSDF to conduct various tests including whether unmanned aircraft can supplant some of the missions currently accomplished with manned aircraft. SeaGuardian is a MALE RPA system that can fly for 24 hours or more, depending on the configuration.GA-ASI has strengthened its Maritime Wide Area Surveillance (MWAS) for Japan with Optix+, which gathers information from the SeaGuardian sensors, as well as other data sources, displaying the full picture of surveillance information for its operator. This functionality makes it easy to task and direct its Intelligence, Surveillance and Reconnaissance (ISR) information in real time. GA-ASI's Optix+ software suite rapidly correlates and exploits collected data into an easily shared common operational picture. Having multi-source correlated data enables automatic detection of anomalous behaviors over waters.SeaGuardian features two multi-mode maritime surface-search radars with an Inverse Synthetic Aperture Radar (ISAR) imaging mode, an Automatic Identification System (AIS) receiver, and a High-Definition - Full-Motion Video sensor equipped with optical and infrared cameras as well as electronic intelligence receivers. This sensor suite enables real-time detection and identification of surface vessels over thousands of square nautical miles and provides automatic tracking of maritime targets and correlation of AIS transmitters with radar and electronic intelligence tracks.About GA-ASIGeneral Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable RPA systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent situational awareness. The company also produces a variety of sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas.For more information, visit www.ga-asi.com .Avenger, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.comSource: General Atomics Aeronautical Systems, Inc. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Military Metals Responds to China’s Export Ban on Critical Minerals ACN Newswire

Military Metals Responds to China’s Export Ban on Critical Minerals

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - December 3, 2024) - Military Metals Corp. (CSE: MILI) (OTCQB: MILIF) (FSE: QN90) (the "Company" or "MILI") a leading North American exploration company focused on critical minerals, acknowledges today's announcement by China banning exports of gallium, germanium, and antimony to the United States. This move underscores the urgent need for Western nations to secure reliable long-term sources of these essential materials.Antimony, a critical component in military applications, energy storage, and advanced manufacturing, is now at the forefront of the global supply chain crisis. China's ban, coupled with existing restrictions that came into effect September 15, 2024, has already sent antimony prices soaring by over 228% this year(1). The Western world faces mounting pressure to address its reliance on China for strategic resources critical to national defense and technological innovation. This ban comes at a time when defense sector inventories are at already concerningly low levels.(2)Military Metals recent antimony mineral project acquisitions in Slovakia, Nova Scotia, and Nevada provide shareholders with a pure antimony play with a diverse portfolio in top jurisdictions."This announcement from China reinforces the importance of Military Metals' mission to secure a sustainable, independent future supply chain for critical minerals," said Scott Eldridge, CEO of Military Metals Corp. "The West can no longer afford to rely on adversarial nations for resources essential to our security and economic stability. We are taking proactive steps to meet this growing demand with future domestic and allied sources of antimony."As geopolitical tensions escalate and the trade war intensifies, Military Metals will continue to prioritize the development of critical mineral resources and work closely with governments and industry partners to ensure the West remains resilient and self-sufficient.About Military Metals Corp. The Company is a British Columbia-based mineral exploration company that is primarily engaged in the acquisition, exploration and development of mineral properties with a focus on antimony.ON BEHALF OF THE BOARD of DIRECTORSFor more information, please contact:Scott EldridgeCEO and Directorscott@militarymetalscorp.comFor enquiries, please call 604-722-5381 or 604-537-7556This news release contains "forward-looking information". Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information in this news release include exploration activities, and assumptions related to the continuation of the global demand for antimony. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. These include, geopolitical developments related to the supply of antimony, the continued use of antimony and availability of alternatives, availability of capital and labour in respect of the properties that are the subjects of this news release, the results of any future exploration activities, which cannot be guaranteed, and such other factors as may impact both and any future activities in respect of the properties.. Additional risk factors can also be found in the Company's public filings under the Company's SEDAR+ profile at www.sedarplus.ca. Forward-looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward looking statements if circumstances, management's estimates or opinions should change, except as required by securities legislation. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.(1)Reuters; China bans export of critical minerals to US as trade tensions escalate; By Amy Lv and Tony Munroe; December 3, 2024(2)Heritage Foundation: commentary/It’s Past Time to Re-Supply Our Munitions-Depleted U.S. Navy by Jim Fein; June 17, 2024To view the source version of this press release, please visit https://www.newsfilecorp.com/release/232325 Copyright 2024 ACN Newswire via SeaPRwire.com.
More

eBRAM Partners with Agency for Volunteer Service to Launch ‘Pro-Bono Online Mediation Scheme for Water Seepage Disputes’

HONG KONG,Dec 3, 2024 - (ACN Newswire via SeaPRwire.com) - In order to resolve conflicts and disputes between property owners and occupants in Hong Kong caused by water seepage issues, eBRAM International Online Dispute Resolution Centre (“eBRAM”), an independent non-profit arbitration and mediation organisation, today joined hands with the Agency for Volunteer Service to officially launch the Pro-bono Online Mediation Scheme for Water Seepage Disputes (“Scheme”). The Scheme is free of charge and aims to foster a harmonious community by providing the public with efficient and economical online mediation services to help resolve water seepage disputes in the community.The Scheme has received strong support from the “Joint Office” set up by the Food and Environmental Hygiene Department and the Buildings Department. When water seepage issues arise, both parties involved can agree to conduct mediation at any stage. The parties can do so by submitting a request through eBRAM’s platform under the Scheme. The platform will then arrange for independent and neutral volunteer mediators to mediate the parties’ dispute. The Scheme aims to enable parties to resolve disputes in the simplest, most cost-effective, and time-efficient manner.Actively Assumes Social Responsibility and Alleviates the Concerns and Difficulties of the CitizensThe issue of building leakage or water seepage is a common source of dispute in the Hong Kong community, and multi-faceted issue encompasses cost split and responsibility for carrying out repairs . This issue has been troubling property owners and occupants in Hong Kong, as it is complicated and involves multiple parties’ responsibilities. Traditional legal proceedings are time-consuming and expensive, making it difficult to resolve these issues in a short period of time, which often causes great suffering to the residents involved.In view of this, as a leading non-profit arbitration and mediation organisation in Hong Kong, eBRAM actively uses innovative approaches to address social livelihood issues. Launched in cooperation with the Agency for Volunteer Service and supported by the Food and Environmental Hygiene Department and the Buildings Department, this free online mediation service fills a gap in legal services and provides an efficient, economical and convenient solution for members of the public who are in need.Efficiently Resolves Water Seepage Disputes, Highlights Advantages of Online MediationeBRAM’s mediation rules and online dispute resolution platform have overcome the time and space limitations of traditional mediation, allowing parties to participate in mediation process anytime and anywhere. Compared with cumbersome litigation procedures, online mediation is fast and efficient, and lowers the threshold for resolving disputes so that both parties do not have to go through lengthy legal proceedings and pay expensive litigation fees. This flexible service model meets the needs of the busy public living in modern cities to build a harmonious community.In addition, mediation is led by the parties involved, who have more control over the outcome. Both parties can work together to agree on a solution, rather than leaving the decision-making process entirely to the court. At the same time, mediation emphasizes fairness and understanding, which aims to reduce tensions between the parties, avoids escalation of conflicts, and protects their neighbourhood relations. As a third party, professional mediators maintain a neutral stance and assist the parties in discussing feasible solutions that give them peace of mind.Innovative LawTech to Help Build a Harmonious FutureDr Thomas So, JP, Chairman of eBRAM, said, "We are committed to serving our society, promoting sustainable development, and giving back to the community by leveraging innovative technologies and applying our expertise. By collaborating with the Agency for Volunteer Service and with the support of the Food and Environmental Hygiene Department and the Buildings Department, the launch of the free ‘Pro-bono Online Mediation Scheme for Water Seepage Disputes’ has not only helped solve the public’s livelihood issues, but also provided new ideas for building a harmonious and inclusive social environment. Looking ahead, we will continue to work closely with the government and other organisations to provide high-quality and efficient dispute resolution services to more members of the public."Ms. Melissa Pang, BBS, MH, JP, Chairman of the Agency for Volunteer Service, said, "We have always been attentive to the needs of the members of the public and are committed to playing a pivotal role in collaborating with various sectors of society to address livelihood issues. By having dedicated professional mediators who are passionate about serving society as volunteer workers, we provide free mediation services to relevant owners and occupants through eBRAM’s online platform, believing that we can play a crucial role in resolving building leakage disputes within the community. We look forward to promoting community harmony through this innovative initiative, ensuring that members of the public can live and work in peace."According to the figures released by the Joint Office, over the past five years, there have been an average of over 40,000 complaints per year on water seepage issues. The number of cases in which the source of water seepage was identified and relevant investigations completed averaged around 5,800 cases per year, accounting for approximately 14.5% of the total number of complaints. As at September 2023, the number of cases under investigation was around 10,000. Between 2020 and 2022, investigation on approximately 30% of the cases could not be completed and complainants were not informed of the investigation results within 90 working days. The “Pro-bono Online Mediation Scheme for Water Seepage Disputes” initiated by eBRAM and the Agency for Volunteer Service is set to effectively reduce the time required to handle water seepage cases, increase efficiency in addressing the public’s livelihood issues, and play a more active role in promoting harmony in the community and reducing social conflicts.“Pro-bono Online Mediation Scheme for Water Seepage Disputes” Webpage:https://ebram.org/Water_Seepage_POM_Scheme/?language=en Copyright 2024 ACN Newswire via SeaPRwire.com.
More

從亞洲到全球 順豐控股開啟新一輪價值躍升

香港, 2024年12月2日 - (亞太商訊 via SeaPRwire.com) - 在中國物流行業,順豐控股(6936.HK)是當之無愧的領跑者。公司從時效快遞起家,通過直營模式,確立在中高端時效快遞領域的領先地位,並率先進行了資源全球化佈局,進行業務的多元化佈局,逐步發展成為業務覆蓋物流行業各核心細分領域的綜合物流服務龍頭。2023年,順豐控股實現營收人民幣2,584億元,在全球綜合物流服務提供商中僅次於聯合包裹服務公司(UPS)、敦豪(DHL)和聯邦快遞(FedEx)。站在行業變革的關鍵時刻,順豐控股將目光從中國及亞洲擴展至全球市場。11月27日,公司於聯交所上市,以期藉助這一契機,加速全球化戰略的推進,助力公司在高質量發展的基礎上,實現新一輪的躍升。新老業務協同發展 新業務陸續迎來盈利增長順豐控股全方位佈局物流業務,其業務版圖覆蓋時效快遞、經濟快遞、快運、冷運物流、同城即時配送以及供應鏈和國際服務領域,在各業務領域均建立領先競爭力。其中,時效快遞作為順豐控股基本盤,2023年市場份額高達63.9%。過往期間,公司持續夯實時效服務競爭力,同時不斷拓展新興產業客群和新業務場景,營收穩步增長,2024年上半年該項業務營收同比增加5.6%。同時,順豐控股新業務也陸續收獲了耕耘果實。快運業務方面,順豐控股在客戶便利性、時效性、准時性等方面持續打造競爭優勢,大件業務於2022年首次實現轉盈,2023年盈利進一步擴大。同城即時配送分部方面,公司通過業務結構優化、精細化管理及科技驅動提升經營能力,2023年首次實現整體盈利,2024年上半年淨利潤擴大至0.62億元。與此同時,順豐控股還通過采取多项降本增效举措,包括推進多網融通,整合天網、地網的物流資源與信息網、優化業務結構以及精益管理等,提升運營效率,促進降本增效。2024年上半年,公司毛利率達到13.6%,較去年同期提升0.3個百分點。可以預見,隨著新業務規模的持續增長以及降本增效效應的加持,公司的盈利水平有望進一步提升。行業景氣度有望延續 國際化拓展高質量成長可期從行業的角度看,物流行業作為經濟的"晴雨表",依然蘊含著巨大的市場機遇。預計2028年,全球物流支出總額將達到13.8萬億美元,2023年至2028年複合年增長率為4.4%。其中,亞洲作為全球規模最大及增長最快的物流市場,且是集中度最低的地區之一,擁有可觀的增長前景,預計2023年至2028年間複合年增長率為5.5%。順豐控股多年經營,於中國市場打下堅實發展根基,品牌形象深入人心。隨後公司深耕中國及亞洲市場,不斷孵化新產品、投資基礎設施,市場份額持續擴大,為未來全球拓展做好準備。未來,順豐控股計劃鞏固其在中國的市場領導地位,同時擴展在亞洲和全球的影響力。在亞洲市場,依託已經建立的龐大的本地物流網絡、廣泛的互通互聯、強大的品牌知名度及團隊,順豐控股有能力複製中國成功經驗,擴展高增長市場。在亞洲以外,利用公司品牌、成本優勢以及綜合物流能力,順豐控股能夠為全球客戶提供具有價格競爭力的一站式解決方案,佔據更大的市場份額。隨著登陸港股資本市場,打造國際化資本運作平台,順豐控股的綜合競爭力也將在資本的助力下得到加強,為國際化戰略加速推進提供有力支持。疊加持續提升其經營能力,公司高質量可持續增長可期。 Copyright 2024 亞太商訊 via SeaPRwire.com.
More

一邦攜手義務工作發展局推出「滲漏糾紛義務網上調解服務」

香港, 2024年12月3日 - (亞太商訊 via SeaPRwire.com) - 為解決本港業主及住戶因樓宇滲水問題所引發的矛盾和糾紛,獨立非營利仲裁調解機構一邦國際網上仲調中心(「一邦」)攜手義務工作發展局,於今天正式推出費用全免的「滲漏糾紛義務網上調解服務」,致力為市民提供高效、經濟的網上調解服務,協助解決社區滲水糾紛,促進鄰里和諧及實現社區共融。該服務計劃獲得由食物環境衞生署及屋宇署組成的「聯合辦事處」(俗稱「滲水辦」)的大力支持,當滲水問題發生後,有關雙方可以在任何階段隨時同意進行調解, 屆時市民可通過由一邦的網站提交聯絡資料及調解申請書,並透過平台安排獨立及中立的義務調解員進行調解。此免費調解服務務求雙方以最簡單、符合效益及省時的方法解決爭議。積極承擔社會責任,為市民解憂緩困樓宇漏水或滲水問題是香港社區中常見的糾紛來源,當中涉及費用分攤、維修責任等不同層面的問題。此民生問題纏擾大量香港業主及住戶、複雜且涉及多方責任。傳統的法律程序既耗時又昂貴,難以在短時間内解決問題,涉事居民均苦不堪言。有見及此,一邦作為香港領先的非營利仲裁調解機構,積極以創新思維解決社會民生議題。本次與義務工作發展局合作、得到食物環境衞生署及屋宇署支持推出的免費義務網上調解服務,彌補了這一項法律服務空白,為有需要的市民提供了一個高效、經濟、便捷的解決途徑。高效解決滲水糾紛,網上調解優勢顯著一邦的調解規則及網上爭議解決平台突破了傳統調解的時間和空間限制,讓當事人可以隨時隨地參與調解過程,相比繁瑣的訴訟程序,網上調解快捷高效,雙方無需經歷冗長的法律程序及昂貴的訴訟費用,降低解決爭議的門檻。這種靈活的服務模式符合現代都市生活繁忙的市民的需求、構建和諧社區。此外,調解過程由當事人主導,當事人擁有對結果的更多控制權,雙方能共同商定解決方案,而非將決策權完全交予法庭。同時,調解強調公平和理解,能緩解雙方的緊張情緒,避免衝突升級,並在一定程度上保護雙方的鄰里關係。而專業調解員作為第三方,秉持中立態度,協助雙方探討可行的解決方案,讓各方安心。創新法律科技,助力構建和諧未來一邦主席蘇紹聰博士表示:「我們一直以服務社會、推動可持續發展為己任,運用創新科技和專業知識回饋社會。此次能夠與義務工作發展局合作,得到食物環境衞生署及屋宇署支持,推出免費的『滲漏糾紛義務網上調解服務』,不僅解決民生問題,更為建設和諧共融的社會環境提供了新思路。未來,一邦將繼續與政府及其他機構緊密合作,為更多市民提供優質、高效的爭議解決服務。」義務工作發展局主席彭韻僖女士表示:「我們一直關注市民需求,並致力承擔樞紐角色,與社會各界建立夥伴關係以解決民生問題。我們招募配對有心服務社會的專業調解員義工,透過一邦的網上法律平台,向相關業主或租戶提供免費的調解服務,相信能在解決樓宇滲漏爭議發揮關鍵作用。我們期待透過是次創新措施,促進社區和諧,使市民都能安居樂業。」根據「滲水辦」的數字顯示,過去5年平均每年接獲逾4萬宗涉及單位滲漏的投訴,成功找出滲水源頭並完成調查的個案數目,平均每年約有5,800宗,佔整體投訴約14.5%。截至2023年9月,仍在進行調查的個案數目約為1萬宗,而在2020至2022年間約有30%的個案未能於90個工作天內完成調查並告知舉報人調查結果。一邦攜手義務工作發展局推動的「滲漏糾紛義務網上調解服務」,相信能夠有效縮減處理滲水個案的時間,提高效率以解決市民的生活問題,並在促進社區和諧、減少社會矛盾方面發揮更大作用。「滲漏糾紛義務網上調解服務」網頁:https://ebram.org/Water_Seepage_POM_Scheme/?language=tc Copyright 2024 亞太商訊 via SeaPRwire.com.
More
#CTS24 Concluded Last Week, Advancing Net-Zero Goals and Sustainable Solutions ACN Newswire

#CTS24 Concluded Last Week, Advancing Net-Zero Goals and Sustainable Solutions

London, UK, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - The 3rd edition of the London Climate Technology Show concluded last week, paving a vital roadmap towards fully decarbonising our planet through sustainable technologies. The event brought together policymakers, eco-technology leaders, industry professionals, and innovators, all unified in their call for an immediate shift to sustainable and green solutions to secure a better future for the planet.The two-day event opened on 27th November with an inspiring keynote by Felicity Burch, Executive Director of the Responsible Technology Adoption Unit at the Department for Science, Innovation, and Technology (DSIT), who spoke about AI Innovation in Clean Energy and the DSIT's Manchester Prize. Following her, Ing. Abigail Cutajar, CEO of the Climate Action Authority, talked about Pioneering the Surge Towards Climate and Energy Transitions.The conference unfolded over two dynamic days, featuring a packed agenda of insightful presentations and engaging panel discussions. It delved into actionable strategies for decarbonisation, advancements in AgriTech, the evolving carbon market, eco-funds, energy, CCS, built environment and other groundbreaking innovations in climate technology.Notable discussions highlighted the need for farmers to balance carbon stewardship with food production over the next few decades, the importance of consistent government policies to enable businesses to plan and innovate effectively, and the urgency of addressing digital and engineering skill shortages to ensure a successful green energy transition. Industry experts also called for common sustainability metrics to measure corporate efforts fairly, emphasized the value of collaboration over competition to accelerate the green transition, and underscored the need for farmers to access landscape-level data to enhance biodiversity.The exhibition hall featured groundbreaking innovations and solutions in sustainability and climate technology, including carbon capture and storage (CCS) from companies like CGI and Terra CO2 Technology, carbon management and accounting solutions by Greenly and Gaia Carbon Accounting, and emerging climate technologies from innovators such as Nabla Flow and Luna 9. Other exhibitors showcased AI-driven solutions, sustainable energy systems, and innovative carbon reduction technologies, presenting a comprehensive snapshot of the future of climate tech.#CTS24 also hosted interactive side events, including startup acceleration programs and hands-on workshops, providing participants with opportunities for learning, networking, and collaboration. These sessions empowered attendees to adopt transformative technologies and take decisive climate action.Attendee ExperiencesThe event received overwhelming positive feedback:Mark Haley, Co-founder of Cero3, shared, "We’re so proud to have unveiled our sustainable travel planner. The feedback and interest exceeded our expectations."Satyajit Mohanan, Projects and Business Development Coordinator at Cambridge Cleantech, remarked, "It was a pleasure to be part of this event. I met amazing people and look forward to the next edition."Dennis Chacko, Senior Sales Manager at the British Board of Agreement, shared his excitement over a unique sustainable pen: "Once used, you can plant it to grow something new—a powerful reminder of how everyday items can contribute to a greener future."As this successful edition concludes, the organisers are already planning for a bigger, more impactful 4th Edition, with expanded content and greater opportunities to drive meaningful change toward a sustainable future.For further information, please reach out to us at press@valiantandcompany.com. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
康哲藥業獲得治療痛風及高尿酸血症的1類新藥獨家商業化權利 ACN Newswire

康哲藥業獲得治療痛風及高尿酸血症的1類新藥獨家商業化權利

深圳, 2024年12月2日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司(以下簡稱「康哲藥業」)欣然宣佈,於2024年12月2日,通過其全資附屬公司與杭州新元素藥業有限公司(以下稱「新元素藥業」,曾用名「江蘇新元素醫藥科技有限公司」)就治療痛風及高尿酸血症的1類新藥ABP-671(「產品」)簽訂獨家商業化協議(「協議」)。根據協議,康哲藥業獲得產品在中國大陸、香港特別行政區及澳門特別行政區的獨家商業化權利。合作期限開始於協議生效之日,自產品首次在中國大陸獲批上市起擁有十年的授權期限(「授權期限」)。授權期限屆滿後,根據協議約定的特定條件,授權期限可自動續期十年。ABP-671是用於治療痛風及高尿酸血症的化藥1類創新藥,目前正分別在中國和境外開展關於痛風的2b/3期臨床試驗,產品通過抑制尿酸鹽轉運蛋白1(URAT1),降低腎臟對尿酸的重吸收。在已經完成的兩項2期臨床試驗結果顯示,ABP-671多個劑量組(1mg至12mg)表現出良好的藥效和安全性。該產品2mg每天單次給藥,其藥效可能相當於或優於苯溴馬隆和非布司他最高劑量80mg的藥效。尿酸下降可維持全天候24小時,沒有出現嚴重的安全性問題。產品有望為痛風及高尿酸血症患者帶來療效更優、安全性更高的治療選擇[1]。與ABP-671相關的化合物和用途方面的多個專利已在中國獲得授權。高尿酸血症是指成人在正常嘌呤飲食情況下,非同日2次空腹血尿酸水平超過420μmol/L (7.0mg/dL)。高尿酸血症患者出現尿酸鹽晶體沉積,導致痛風性關節炎,稱為痛風。高尿酸血症及痛風可引起關節軟骨、骨質、腎臟以及血管壁等急慢性炎症損傷,導致心、腦、腎等多器官損害。《2021中國高尿酸及痛風趨勢白皮書》數據顯示,我國高尿酸血症的總體的患病率為13.3%,高尿酸血症患病人數約1.77億人,痛風總體發病率為1.1%,患病人數約為1,466萬。據弗若斯特沙利文分析,未來中國高尿酸血症和痛風患病人數會持續增加,將在2030年分別達到2.4億人、5,220萬人。目前我國臨床上常用的降尿酸藥物主要包括抑制尿酸合成和促進尿酸排泄兩類,由於已上市降尿酸藥物在療效和安全性上仍存在一定的局限性,如導致腎衰竭、心臟猝死或嚴重肝臟毒性等。中國痛風及高尿酸血症患者對高效安全的降尿酸藥物仍然有迫切的需求。ABP-671是當前痛風及高尿酸血症治療中潛在療效優、安全性好的產品。通過本次合作引進,填補了康哲藥業痛風治療產品的空白。痛風及高尿酸血症既屬於風濕疾病又屬於慢性代謝性疾病,與康哲藥業心腦血管/消化業務的戰略佈局,以及在售品種的網絡資源高度契合。ABP-671如未來獲批上市,在風濕免疫科可與在售產品美泰彤(甲氨蝶呤注射液),在內分泌科和骨科可與益蓋寧(依降鈣素注射液)在專家網絡與市場資源方面協同。基於未滿足的臨床需求和產品預期扎實的臨床數據,期待ABP-671的臨床開發工作順利推進,使相關適應症患者儘快從創新療法中獲益。關於新元素藥業新元素藥業創辦於2012年3月,專注於代謝和炎症領域疾病中具有全球商業價值和全球競爭力的創新藥的研發。新元素藥業主要核心團隊人員來自美國,具有廣泛的創新藥物的研發經驗,過去幾年新元素藥業取得了顯著的發展成果。其核心產品ABP-671正處於後期臨床研發階段,用於治療慢性痛風;另一個小分子創新藥物ABP-745用於抗炎自免領域適應症,已完成1期臨床,表現出良好的PK和安全性,即將進入2期臨床。有關新元素藥業及其產品的更多信息,請訪問其官方網站:https://www.atombp.com/。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化,把控產品全生命週期管理的開放式平臺型企業,致力於提供有競爭力的產品和服務,滿足尚未滿足的醫療需求。康哲藥業專注於全球首創(FIC)及同類最優(BIC)的創新產品,並高效推進創新產品臨床研究開發和商業化進程,賦能科研成果向診療實踐的持續轉化,造福患者。康哲藥業聚焦專科領域,擁有被驗證的商業化能力,廣泛的渠道覆蓋和多疾病領域專家資源,核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展,以鞏固心腦血管/消化業務競爭力,並將皮膚醫美、眼科業務獨立運營,培育專科小領域的大龍頭,提升專科規模效率。同時業務版圖拓展至東南亞市場,著力成為全球藥企進軍東南亞市場的「橋頭堡」,助力康哲藥業高質量持續健康發展。參考文獻:1.產品2期臨床試驗結果已發佈,詳情如下:https://www.atombp.com/2023/03/01/atom-bioscience-announces-positive-results-of-phase-2a-china-clinical-trial-of-its-urat1-inhibitor-for-chronic-gout/康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣,非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療信息,請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請,不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制,但康哲藥業並無進行任何說明或保證、明述或暗示,或其他表述,對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述,該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證,存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測,康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2024 亞太商訊 via SeaPRwire.com.
More
15 Companies Pitch Their Capabilities at GA-ASI’s Blue Magic Netherlands ACN Newswire

15 Companies Pitch Their Capabilities at GA-ASI’s Blue Magic Netherlands

SAN DIEGO, CA, Dec 3, 2024 - (ACN Newswire via SeaPRwire.com) - On November 19, 2024, General Atomics Aeronautical Systems, Inc. (GA-ASI) hosted its first Blue Magic Netherlands (BMN) event in Eindhoven, the Netherlands. Approximately 200 people attended the event that provided Dutch businesses with an opportunity to present their capabilities to GA-ASI and other companies interested in possible collaborations. GA-ASI was joined for the event by the Netherlands Ministry of Economic Affairs, the Netherlands Ministry of Defence, Lockheed Martin Ventures, Brainport Development, Brabant Development Agency (BOM), the Netherlands Industries for Defence & Security (NIDV), and SpaceNED.At this event, GA-ASI and its partners heard first-hand from Dutch companies about the important capabilities they are developing. The process started in July when GA-ASI put out an open invitation to Dutch businesses to apply for the opportunity to present innovative technologies at the November 19 event. Key areas of focus included Artificial Intelligence/Machine Learning, Autonomy, Advanced Materials, Sensors, Advanced Manufacturing, and Space. Close to 50 companies applied and after reviewing the applications, 15 businesses were selected to pitch their capabilities to an audience that included lightweight lattice structures, gas detection technologies, advanced battery and photonics applications, and several innovative unmanned system and AI applications, among many others."This event is where the rubber meets the road," said Brad Lunn, Managing Director-Strategic Finance at GA-ASI. "In addition to attracting many companies, we increased the areas of expertise and depth of knowledge from the presenting companies in order to provide research, development, and breakthrough innovations to support current and future missions by GA-ASI aircraft. We also wanted to give the companies an opportunity to pitch in front of other potential customers, partners, and investors."The first Blue Magic event held by GA-ASI was in 2019 in Belgium, with subsequent events held in 2020, 2021, and 2023. GA-ASI is delivering eight MQ-9A Remotely Piloted Aircraft to the Royal Netherlands Air Force (RNLAF).GA-ASI expects to announce technology partnerships stemming from the BMN event and intends to hold this event on an annual basis in the Netherlands.About GA-ASIGeneral Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable remotely piloted aircraft (RPA) systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent flight that enables situational awareness and rapid strike. The company also produces a variety of ground control stations and sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas. For more information, visit www.ga-asi.com.Avenger, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.comSource: General Atomics Aeronautical Systems, Inc. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Advancing the Belt and Road Initiative: The Kyrgyz Republic Ministry of Finance’s First Promotional Seminar and Non-Deal Roadshow Successfully Held ACN Newswire

Advancing the Belt and Road Initiative: The Kyrgyz Republic Ministry of Finance’s First Promotional Seminar and Non-Deal Roadshow Successfully Held

HONG KONG, Dec 3, 2024 - (ACN Newswire via SeaPRwire.com) - December 2, 2024, In the context of the Belt and Road Initiative, the first Belt and Road Golden Route Series Financial Promotion Event——the Kyrgyz Republic Ministry of Finance's promotional seminar and non-deal roadshow was successfully held today in Hong Kong. The event was jointly hosted by TF International Securities Group Limited ("TF International") and China CITIC Bank International Limited ("China CITIC Bank International"), attracting numerous international investors and financial industry leaders.The Kyrgyz Republic, as one of the earliest countries to support and engage in the Belt and Road Initiative, has seen increasingly close economic and trade relations with China. Recently, TF International signed a memorandum of understanding with the Kyrgyz Republic Ministry of Finance, becoming the first Hong Kong-based Chinese securities firm to establish an official partnership with the Kyrgyz Republic Ministry of Finance. The two parties work together to promote the RMB internationalization, support the real economy, facilitate high-quality development, and reinforce Hong Kong’s position as an international financial center. The event featured distinguished guests, including Mr. Amanbaev Umutzhan Mominovich, Deputy Minister of Finance of Kyrgyz Republic, Mr. Abdybapov Abdanbek Abdybapovich, Head of the Government Borrowing Department of Kyrgyz Republic, Mr. CHAN Ho Lim, Joseph, JP, Under Secretary for Financial Services and the Treasury of Hong Kong S.A.R., and Mr. ZOU Chuan, CEO of TF International, as well as Mr. Andy Siow, Senior Coverage Banker, DCM, at China CITIC Bank International. They shared insights into Kyrgyzstan’s development opportunities and investment prospects in the international financial market, discussing investment opportunities and key focus areas for mutually beneficial cooperation. In his opening speech, Mr. CHAN Ho Lim, Under Secretary for Financial Services and the Treasury of Hong Kong, remarked, "Hong Kong has firmly established itself as Asia’s leading international financial centre. Our core strengths include free flow of capital and information, a robust common law system, and a simple and low tax regime, and Hong Kong enjoys preferential access to Mainland China. All these position Hong Kong as the super-connector between China and international markets, which plays a key role in promoting RMB internationalization and advancing the Belt and Road Initiative. The Kyrgyz Republic is an important partner under the Belt and Road Initiative and is certainly Hong Kong’s important trading partner in Central Asia.” He also stated that, “I would like to express my gratitude to the Kyrgyz Republic Ministry of Finance and TF International and appreciate your commitment to fostering stronger ties between Central Asia and Hong Kong. We look forward to exploring potential future collaborations with the Kyrgyz Republic that will benefit our respective markets and promote partnerships among Belt and Road nations.” As of September 1, 2024, Renminbi (RMB) has been included in the list of official daily exchange rates published by Kyrgyzstan, alongside the US dollar, euro, Russian ruble, and Kazakh tenge. This move further strengthens economic and financial cooperation between the two countries. Mr. Amanbaev Umutzhan Mominovich, Deputy Minister of Finance of the Kyrgyz Republic, stated, "The inclusion of the RMB in the list of official daily exchange rates in Kyrgyzstan marks a new stage in the economic cooperation between the two countries. This not only provides greater convenience for international investors but also empowers the development of Kyrgyzstan's financial market. Through this promotional event, we hope to connect with more international investment institutions and jointly promote the sustainable development of the regional economy." Hong Kong, as the international financial center and the central city of the Guangdong-Hong Kong-Macao Greater Bay Area, plays an important bridging role in the Belt and Road Initiative, leveraging its diverse financing channels and close alignment with national strategies. Mr. ZOU Chuan, CEO of TF International, stated, "The Belt and Road Initiative offers significant opportunities for economic integration and development, enhancing trade across Asia, Europe, the Middle East, and beyond. As a gateway between China and the world, Hong Kong is a key hub for the internationalization of the Renminbi, facilitating its use in trade and investment, and supporting effective currency risk management for BRI projects. With ongoing economic expansion and the internationalization of the Renminbi, Hong Kong is well-positioned to emerge as the premier financing hub. As we explore upcoming opportunities, I encourage you to envision the transformative impact these initiatives can have on the Kyrgyz Republic’s development agenda and the broader economic landscape of Central Asia. Together, we can unlock new avenues for growth and collaboration." From December 3 to 6, 2024, TF International, in collaboration with China CITIC Bank International will join forces with the Kyrgyz Republic Ministry of Finance in hosting a series of non-deal roadshows in Shanghai and Beijing, further strengthening ties with the Chinese financial market. The success of today’s promotional seminar and non-deal roadshow in Hong Kong marks a new milestone in the economic cooperation between the two countries and injects fresh momentum into the high-quality development of the Belt and Road Initiative. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
共建一帶一路:吉爾吉斯斯坦國家財政部首場推介會暨非交易性路演成功舉行 ACN Newswire

共建一帶一路:吉爾吉斯斯坦國家財政部首場推介會暨非交易性路演成功舉行

香港, 2024年12月3日 - (亞太商訊 via SeaPRwire.com) - 2024年12月2日,在「一帶一路」倡議的背景下,由天風國際證券集團有限公司(以下簡稱「天風國際」)與中信銀行(國際)有限公司(以下簡稱「信銀國際」)聯合主辦的首場「一帶一路」黃金線系列金融推介會——吉爾吉斯斯坦國家財政部推介會暨非交易性路演於今日在香港圓滿舉行。本次活動吸引了眾多國際投資機構及金融行業領袖出席。吉爾吉斯斯坦作為最早支持和參與「一帶一路」倡議的國家之一,近年來與中國的經貿合作關係日益密切。近期,天風國際與吉爾吉斯斯坦國家財政部簽訂合作備忘錄,成為首家與吉爾吉斯斯坦國家財政部建立合作關係的駐港中資券商。雙方將就共同推動人民幣國際化願景,服務實體經濟,助力高質量發展,為維持並進一步鞏固香港作為國際金融中心的地位,展開更廣泛的合作。本次活動邀請了多位重量級嘉賓,包括吉爾吉斯斯坦國家財政部副部長Amanbaev Umutzhan Mominovich先生、政府借貸部主任Abdybapov Abdanbek Abdybapovich先生、香港特別行政區政府財經事務及庫務局副局長陳浩濂太平紳士,以及天風國際行政總裁鄒傳先生和信銀國際高級董事、債券資本市場、財資及環球市場Andy Siow先生。會上,嘉賓們分享了吉爾吉斯斯坦在參與國際金融市場的發展機遇與其投資前景,共同探討了雙方互利共贏的合作著力點。陳浩濂副局長在致辭中表示:「香港作為全球主要國際金融中心,具備資本與信息的自由流動、穩健的普通法制度以及單一稅制等核心優勢,同時香港與中國內地市場聯繫緊密,在促進人民幣國際化和推動『一帶一路』倡議中發揮著關鍵作用。而吉爾吉斯斯坦作為『一帶一路』倡議下的重要合作夥伴,毫無疑問,也是香港在中亞地區的重要貿易夥伴。感謝天風國際的精心組織和吉爾吉斯斯坦代表團的到訪,今天我們齊聚一堂,探討如何進一步加强中亞與香港之間的經濟合作。我們期待未來與吉爾吉斯斯坦的合作將為兩國經濟增長注入新的動力,推動『一帶一路』國家之間的多層次合作,進一步促進區域經濟的可持續發展。」自2024年9月1日起,人民幣已正式列入吉爾吉斯斯坦官方每日公佈匯率的貨幣名單,與美元、歐元、俄羅斯盧布和哈薩克斯坦堅戈一起,成為吉爾吉斯斯坦每日公佈匯率的貨幣,這一舉措進一步深化了兩國在經濟與金融領域的合作。吉爾吉斯斯坦國家財政部副部長Amanbaev Umutzhan Mominovich先生在會上表示:「人民幣成功納入吉爾吉斯斯坦官方每日公佈匯率的貨幣名單,標誌著兩國經濟合作進入了新的階段。這不僅為國際投資者提供了更多便利,也為吉爾吉斯斯坦的金融市場發展賦能。我們希望通過此次推介會,與更多國際投資機構建立聯繫,共同推動區域經濟的可持續發展。」香港作為國際金融中心,同時也是粵港澳大灣區的核心城市,憑藉多樣的融資渠道和與國家戰略的深度對接,在「一帶一路」倡議中發揮了重要的橋梁作用。作為此次活動的聯合主辦方之一,天風國際行政總裁鄒傳先生在致辭中提到:「『一帶一路』倡議為經濟一體化和發展提供了巨大機遇,推動亞歐、中東乃至更廣泛地區的貿易往來。香港作為中國市場聯通世界的重要窗口,同時也是人民幣國際化的關鍵樞紐,促進人民幣在貿易和投資中的使用,支持『一帶一路』項目的融資與匯率風險管理。隨著人民幣國際化的推進,香港正穩步成為全球領先的融資中心。在探索未來機遇的同時,期待今日的活動與市場洞察的深入分享,對吉爾吉斯斯坦發展進程以及中亞經濟帶來積極、深遠的影響。」後續,天風國際聯合信銀國際將陪同吉爾吉斯斯坦國家財政部於12月3日至6日期間,陸續在上海和北京繼續舉辦系列非交易性路演活動,進一步深化吉爾吉斯斯坦與中國金融市場的聯繫。此次香港推介會的成功舉辦標誌著兩國在經濟領域合作邁向新高度,為「一帶一路」倡議的高質量發展注入了新動能。 Copyright 2024 亞太商訊 via SeaPRwire.com.
More
Edvantage Group Announces FY2024 Annual Results ACN Newswire

Edvantage Group Announces FY2024 Annual Results

Highlights (relevant audited data for the year ended 31 August 2024)- Revenue increased by 17% YoY to approximately RMB2,312 million;- Gross profit rose by 10% YoY to approximately RMB1,124 million;- Profit for the period attributable to owners of the Company rose by 16% YoY to approximately RMB715 million;- Number of student enrolments increased by 11% YoY to approximately 95,600;- Payment of a final dividend of HK10.0 cents per share;- Dividend payout ratio of 30% for the year.HONG KONG, Nov 29, 2024 - (ACN Newswire via SeaPRwire.com) - Edvantage Group Holdings Limited (“Edvantage Group” or the “Group”, stock code: 0382.HK) has announced its audited FY2024 Annual Results for the year ended 31 August 2024 (the “Reporting Period”). During the Reporting Period, the Group actively responded to national policies, vigorously promoted industry-education integration, deepened the connotations of international education, continued to introduce unique new featured majors that match market and industry demands and fully embraced artificial intelligence (“AI”), succeeding in raising education quality and brand presence, thereby achieving steady growth in performance year after year.During the Reporting Period, the Group’s revenue totaled approximately RMB2,312 million, representing an increase of 17% as compared to the corresponding period of the preceding year. The increase was mainly attributable to the continuous enhancement of the Group’s education brand effectiveness, which drove a rise in the number of student enrolments and higher average tuition fees recorded by the Group’s domestic schools. Profit for the period attributable to owners of the Company rose by 16% YoY to approximately RMB715 million. The number of students enrolled in the Group’s schools continued to expand yearly, reaching approximately 95,600, with a year-on-year growth of approximately 11%. The Board of Directors of the Group has recommended the payment of a final dividend of HK10.0 cents per share for the year ended 31 August 2024, which, along with an interim dividend of HK9.6 cents per share, equates to a total annual dividend of HK19.6 cents per share and a dividend payout ratio of 30% for the year.From left to right: Mr. Yan Kwok Ting Sunny, Director of Investment, Corporate Finance & Investor Relations Department;Mr. Liu Yuk Tung, ChiefFinancial Officer; Ms. Liu Yi Man, Executive Director and Chief Executive Officer;Ms. Liu Wenqi, Chief Operating Officer;Fully embracing AI and continuously promoting the industry-education integrationOver the past year, the Group witnessed the groundbreaking development of the new generation of artificial intelligence technology. As a vocational education provider, the Group has developed in step with times, fully embracing AI in teaching, management and application. At present, all of its schools are actively promoting AI, fostering its popularity, with AI-embedded courses launched in seven colleges. Subsequent efforts will be made to promote those programmes to cover all faculties and students of all schools under the Group. Meanwhile, the Group actively responded to national policies, continuously deepened industry-education integration, and fully promoted the construction of industrial colleges, cooperating with multiple enterprises renowned in their respective industries to establish artificial intelligence and big data, digital trade, digitalised accounting and business services, research and tourism, jewelry, human resources and other industrial colleges. Those industrial colleges are all set up according to the Ministry of Education requirements for building modern industrial colleges that align with the country’s key industry development strategies, in order to nurture high-quality application-minded talent that emerging industries urgently need. In addition, the Group also entered into school-enterprise cooperation with numerous enterprises to build off-campus practice bases, further promoting the in-depth integration of education chains and industrial chains.Expanding exchange and cooperation of international education and deepening the connotations of international educationThe Group responded to the national advocacy for the opening up of education, “introduction of foreign schools”, and “international expansion of domestic schools”, continuously promoted the internationalisation of vocational education and expanded the partnership network with global renowned universities. By providing high-quality international programs and practice opportunities to students, the Group aims to cultivate innovative talents with global vision, to further raise the international influence of China’s vocational education. During the Reporting Period, the schools under the Group established in-depth cooperation with 51 foreign high schools in the United States of America, the United Kingdom, Canada, Japan and Australia, joining hands to create diverse high-quality international programmes. Furthermore, the Group comprehensively launched international study tours, organising 65 student and teacher study tours to France, Singapore, Hong Kong, China, Macau, China and other regions for short-term studies, with over 4,000 teachers and students participating during the Reporting Period. Looking forward, the Group will press on with deepening integration of its schools - domestic and international, strive to build a diversified international education cooperation network, actively promote Chinese vocational education to go global and build an internationally renowned Chinese vocational education brand.Consistently increasing investment in education to build a high-quality education brandThe Group has always adhered to the motto of "Establishing school of the century, Nurturing talents of the nation". Firmly believing that increasing investment in education is an important path towards high-quality education, the Group further expanded the new campus of Guangzhou Huashang College and Guangzhou Huashang Vocational College during the Reporting Period, which includes student dormitories, library, sports centre, teaching buildings and laboratories, providing solid support for future student enrollment and sustainable development of the Group. At the same time, it has kept increasing investment in building a high-quality teaching staff, which has expanded after the Guangzhou Huashang College and Guangzhou Huashang Vocational College established their Guangdong Province Doctoral Workstation respectively. The Group has launched a series of training workshops for teachers to continuously enhance their professionalism and practical teaching abilities, encouraging them to practice what they have learned and help improve school education and teaching quality. By introducing mentors from industries, it works together with enterprises in nurturing professional “dual-qualified” teachers and “dual-skilled” industry mentors, continuing to optimize the combined structure of full-time and part-time faculty teams. The in-depth and precise investment made by the Group in various areas crucial to strengthening school management has brought bountiful results. Guangzhou Huashang College placed third in scientific research competitiveness among private undergraduate colleges in China and has been designated as a key research base for humanities and social sciences among regular higher education institutions in Guangdong Province. Guangzhou Huashang Vocational College has been named a national exemplary vocational college, while the Urban Vocational College of Sichuan ranked second in China and first in Sichuan among Shanghai Ranking's 2024 Best Chinese Private Higher Vocational Colleges. These honors are a strong testament to the Group’s high-quality educational achievements.Looking ahead, the Group will continue to nurture innovative talent, focusing on such areas as industry and education integration, internationalization, and AI to keep up with industry and social development needs, increase investment in education, and keep building a high-quality education brand. It is committed to nurturing highly-skilled interdisciplinary corporate leaders for the country and industries around the world, while continuously making positive contributions to the sustainable development of vocational education.About Edvantage Group Holdings LimitedEdvantage Group Holdings Limited (“Edvantage Group” or the “Group”, stock code: 0382.HK) is the largest private business higher education and vocational education group in the Greater Bay Area, and an early mover in education sector in pursuing international expansion, listed in Hong Kong Main Board on 16 July 2019. The total number of full-time student enrolments of the Group was approximately 96,000 as of 31 August 2024. Operated 9 private education institutions, namely, Guangzhou Huashang College (Applied Undergraduate), Guangzhou Huashang Vocational College (Higher Vocational Education) and Guangdong Huashang Technical School (Secondary Vocational Education) located in Guangdong Province, the PRC; Urban Vocational College of Sichuan (Higher Vocational Education) and Urban Technician College of Sichuan (Secondary Vocational Education) in Sichuan Province, the PRC; GBA Business School (GBABS) in Hong Kong, the PRC; Global Business College of Australia (GBCA) and Edvantage Institute Australia (EIA) in Australia; as well as Edvantage Institute (Singapore) (EIS) in the downtown of Singapore.While focusing on school operations, the Group also actively fulfil corporate social responsibility, extensively contributing to social welfare programmes including charity, poverty alleviation, education and revitalisation, in order to take the initiative in repaying society through action. Since its listing, the Group has made outstanding contributions in the field of ESG and has won the “Best ESG Innovation Award” from Zhitong Finance and the “Outstanding Enterprise for ESG Innovative Practice” from Gelonghui in 2024. Copyright 2024 ACN Newswire via SeaPRwire.com.
More